Affiance Financial’s Medifast MED Stock Holding History

Affiance Financial’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-51	Closed	-$5.88K	–	287
2022 Q4	$5.88K	Buy	+51	New	+$5.94K	﹤0.01%	330

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Affiance Financial's MED Position: Q1 2023 in Review

Affiance Financial sold out of Medifast (MED) in Q1 2023, closing a stake of 51 shares — an estimated $5.88K sold.

Affiance Financial first reported a position in MED in Q4 2022 and held it in 1 quarter. The position peaked at $5.88K in Q4 2022. 267 funds tracked by Wall St. Rank hold MED as of Q1 2023.

Affiance Financial reported no remaining Medifast position as of Q1 2023 after selling out during the quarter.
Affiance Financial sold 51 Medifast shares in Q1 2023, an estimated $5.88K.
Affiance Financial first reported a position in Medifast in Q4 2022 and held it in 1 quarter.
Affiance Financial's Medifast position peaked at $5.88K in Q4 2022.
267 funds tracked by Wall St. Rank held Medifast as of Q1 2023.

Based on Affiance Financial's 13F filing for Q1 2023, filed 18 Apr 2023.